AR121842A1 - Compuesto de benzimidazol para el tratamiento de trastornos metabólicos - Google Patents

Compuesto de benzimidazol para el tratamiento de trastornos metabólicos

Info

Publication number
AR121842A1
AR121842A1 ARP210100985A ARP210100985A AR121842A1 AR 121842 A1 AR121842 A1 AR 121842A1 AR P210100985 A ARP210100985 A AR P210100985A AR P210100985 A ARP210100985 A AR P210100985A AR 121842 A1 AR121842 A1 AR 121842A1
Authority
AR
Argentina
Prior art keywords
benzimidazole compound
treatment
metabolic disorders
metabolites
solvates
Prior art date
Application number
ARP210100985A
Other languages
English (en)
Inventor
De Azevedo Hatylas Felype Zaneti
Junior Marcos Antonio Ferreira
Natanael Dante Segretti
Alessandra Mascarello
Guimares Cristiano Ruch Werneck
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of AR121842A1 publication Critical patent/AR121842A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención, de manera general, concierne a un compuesto de benzimidazol de fórmula (1) para el tratamiento de la obesidad, la diabetes, la enfermedad del hígado graso no alcohólica y la esteatohepatitis no alcohólica: o sales, cristales, hidratos, profármacos, metabolitos o solvatos farmacéuticamente aceptables del mismo. Reivindicación 1: Un compuesto de bencimidazol de la fórmula (1) o sales, cristales, hidratos, solvatos, prodrogas o metabolitos del mismo farmacéuticamente aceptables.
ARP210100985A 2020-04-15 2021-04-14 Compuesto de benzimidazol para el tratamiento de trastornos metabólicos AR121842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063010128P 2020-04-15 2020-04-15

Publications (1)

Publication Number Publication Date
AR121842A1 true AR121842A1 (es) 2022-07-13

Family

ID=78083461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100985A AR121842A1 (es) 2020-04-15 2021-04-14 Compuesto de benzimidazol para el tratamiento de trastornos metabólicos

Country Status (15)

Country Link
US (1) US20230128304A1 (es)
EP (1) EP4136079A4 (es)
JP (1) JP2023522062A (es)
KR (1) KR20230002427A (es)
CN (1) CN115335363A (es)
AR (1) AR121842A1 (es)
AU (1) AU2021256476A1 (es)
CA (1) CA3171746A1 (es)
CL (1) CL2022002821A1 (es)
CO (1) CO2022012616A2 (es)
EC (1) ECSP22078679A (es)
GB (1) GB2609793B (es)
MX (1) MX2022009872A (es)
PE (1) PE20221568A1 (es)
WO (1) WO2021207816A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
ES2331274B1 (es) * 2007-10-25 2010-10-21 Ferrer Internacional, S.A. Compuesto de indolina.
MX2011003239A (es) * 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
ES2711808B2 (es) * 2017-11-02 2020-03-13 Univ Granada Uso de un agonista de melatonina para inducir la para inducir adipocitos beige en el tejido adiposo blanco

Also Published As

Publication number Publication date
MX2022009872A (es) 2022-08-22
GB202215434D0 (en) 2022-11-30
AU2021256476A1 (en) 2022-08-25
CN115335363A (zh) 2022-11-11
WO2021207816A1 (en) 2021-10-21
CA3171746A1 (en) 2021-10-21
ECSP22078679A (es) 2022-11-30
GB2609793A (en) 2023-02-15
CL2022002821A1 (es) 2023-04-10
EP4136079A4 (en) 2024-05-15
JP2023522062A (ja) 2023-05-26
PE20221568A1 (es) 2022-10-06
US20230128304A1 (en) 2023-04-27
GB2609793A8 (en) 2023-03-22
CO2022012616A2 (es) 2022-10-21
GB2609793B (en) 2024-05-08
KR20230002427A (ko) 2023-01-05
EP4136079A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ES2529890T3 (es) Agentes para el tratamiento de trastornos que implican la modulación de los receptores rianodina
JOP20190182B1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
CO2021009240A2 (es) Compuestos moduladores de fxr (nr1h4)
SV2009003146A (es) Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct)
CU20190080A7 (es) Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis
AR067538A1 (es) Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa
AR069165A1 (es) Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
MA41389A1 (fr) Utilisation de sulfones tricycliques en tant que modulateurs de rory
NZ721645A (en) Compounds for use as gpr120 agonists
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
CL2022001357A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
BR112022018515A2 (pt) Terapia de combinação para leucemia mieloide aguda
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
MX2023003825A (es) Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.